Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keros Therapeutics, Inc.

14.07
+0.54003.99%
Post-market: 14.05-0.0200-0.14%19:47 EDT
Volume:1.35M
Turnover:18.88M
Market Cap:570.71M
PE:-2.81
High:14.20
Open:13.42
Low:13.42
Close:13.53
Loading ...

Company Profile

Company Name:
Keros Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
169
Office Location:
1050 Waltham Street,Suite 302,Lexington,Massachusetts,United States
Zip Code:
02421
Fax:
- -
Introduction:
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Directors

Name
Position
Jasbir Seehra
Chief Executive Officer and Director
Alon Lazarus
Director
Carl Gordon
Director
Julius Knowles
Director
Nima Farzan
Director
Ran Nussbaum
Director
Tomer Kariv
Director

Shareholders

Name
Position
Jasbir Seehra
Chief Executive Officer and Director
Keith Regnante
Chief Financial Officer
Claudia Ordonez
Chief Medical Officer
Jennifer Lachey
Chief Scientific Officer